Health Impact 360: Advancing Physical, Social, and Mental Health Among Marginalized Communities for Cardiovascular Health Equity
Launched by UNIVERSITY OF MICHIGAN · Jun 23, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called Health Impact 360, is studying a program designed to improve heart health and overall well-being in adults from marginalized communities. The program focuses not just on physical health, but also on mental health and social support, aiming to help participants reduce stress, feel more connected to others, and improve their heart health over 16 weeks. Researchers want to see if people who take part in this program do better than those who wait to join.
Adults between the ages of 65 and 74 who speak English or Spanish and can participate in group sessions may be eligible to join. Pregnant individuals are not eligible because pregnancy can affect some health measurements. Participants will attend group meetings twice a week for the first 8 weeks, then once a week for the next 8 weeks. They will also wear a pedometer to track their physical activity and complete surveys and health measurements at the start and end of the study. Those who engage more fully with the program are expected to see the greatest benefits.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English or Spanish speaking
- • Able to participate in group-based programming
- Exclusion Criteria:
- • - All pregnant persons to prevent pregnancy-related biometric changes from biasing outcome analyses
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Patients applied
Trial Officials
Jennifer Garner, PhD, RD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported